PubMed Health⌕ Search

PubMed · 12689052

Crossover in diffusion equation: anomalous and normal behaviors.

Abstract

Ubiquitous phenomena exist in nature where, as time goes on, a crossover is observed between different diffusion regimes (e.g., anomalous diffusion at early times which becomes normal diffusion at long times, or the other way around). In order to focus on such situations we have analyzed particular relevant cases of the generalized Fokker-Planck equation integral dgamma(')tau(gamma('))[ partial differential (gamma('))rho(x,t)]/ partial differential t(gamma('))= integral dmu(')dnu'D(mu('),nu('))[ partial differential (mu('))[rho(x,t)](nu('))]/ partial differential x(mu(')), where tau(gamma(')) and D(mu('),nu(')) are kernels to be chosen; the choice tau(gamma('))=delta(gamma(')-1) and D(mu('),nu('))=delta(mu(')-2)delta(nu(')-1) recovers the normal diffusion equation. We discuss in detail the following cases: (i) a mixture of the porous medium equation, which is connected with nonextensive statistical mechanics, with the normal diffusion equation; (ii) a mixture of the fractional time derivative and normal diffusion equations; (iii) a mixture of the fractional space derivative, which is related with Lévy flights, and normal diffusion equations. In all three cases a crossover is obtained between anomalous and normal diffusions. In cases (i) and (iii), the less diffusive regime occurs for short times, while at long times the more diffusive regime emerges. The opposite occurs in case (ii). The present results could be easily extended to more complex situations (e.g., crossover between two, or even more, different anomalous regimes), and are expected to be useful in the analysis of phenomena where nonlinear and fractional diffusion equations play an important role. Such appears to be the case for isolated long-ranged interaction Hamiltonians, which along time can exhibit a crossover from a longstanding metastable anomalous state to the usual Boltzmann-Gibbs equilibrium one. Another illustration of such crossover occurs in active intracellular transport.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E K Lenzi, R S Mendes, C Tsallis. 2003-03-19. Crossover in diffusion equation: anomalous and normal behaviors.. https://doi.org/10.1103/physreve.67.031104

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗